9 % LAVOISIER

DRUG3 trials

Sponsors

Assistance Publique Hopitaux De Paris, St. Olavs Hospital HF, Centre Hospitalier Et Universitaire De Limoges

Conditions

Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery.Sustained immunosuppressionvaso-occlusive crisis due to sickle cell disease

Phase 3

Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department: a Double Blind Randomized versus placebo Controlled Trial (INVOPE)

RecruitingCTIS2023-504847-15-00

Assistance Publique Hopitaux De Parisvaso-occlusive crisis due to sickle cell disease

Start: 2025-07-21Target: 915Updated: 2025-12-22

Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial

RecruitingCTIS2024-516780-93-00

Centre Hospitalier Et Universitaire De LimogesSustained immunosuppression

Start: 2025-07-09Target: 326Updated: 2025-05-27

Phase 4

A parallel-group treatment, Phase 4, prospective multicenter double-blind randomized 2-arm placebo-controlled study to investigate the effect of single dose topical administration of tranexamic acid vs placebo onto surgical wound surfaces on postoperative re-bleeding, wound complications, seroma and thromboembolic events in male and female patients above 18 years of age undergoing plastic surgery.

RecruitingCTIS2023-510381-28-01

St. Olavs Hospital HFPatients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery.

Start: 2024-09-18Target: 3500Updated: 2025-09-14

Related Papers

Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial.

2026-01-27